KRAS, BRAF, and PIK3CA mutations as predictors of outcome of maintenance therapy with bevacizumab with or without erlotinib after first line combination chemotherapy for mCRC. Results of the phase III Nordic ACT trial NCT00598156 translational study

Karen-Lise Garm Spindler; René dePont Christensen; Rikke Fredslund Andersen; Niels Pallisgaard; Anders Johnsson; Anders Jakobsen

KRAS, BRAF, and PIK3CA mutations as predictors of outcome of maintenance therapy with bevacizumab with or without erlotinib after first line combination chemotherapy for mCRC. Results of the phase III Nordic ACT trial NCT00598156 translational study

Karen-Lise Garm Spindler, René dePont Christensen, Rikke Fredslund Andersen, Niels Pallisgaard, Anders Johnsson, Anders Jakobsen

Research output: Contribution to conference without publisher/journal › Poster › Research › peer-review

Original language	English
Publication date	2012
Publication status	Published - 2012
Event	The 24th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics - Dublin, Ireland Duration: 6. Nov 2012 → 9. Nov 2012

Conference

Conference	The 24th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Country/Territory	Ireland
City	Dublin
Period	06/11/2012 → 09/11/2012

Cite this

Spindler, K.-L. G., Christensen, R. D., Fredslund Andersen, R., Pallisgaard, N., Johnsson, A., & Jakobsen, A. (2012). KRAS, BRAF, and PIK3CA mutations as predictors of outcome of maintenance therapy with bevacizumab with or without erlotinib after first line combination chemotherapy for mCRC. Results of the phase III Nordic ACT trial NCT00598156 translational study. Poster session presented at The 24th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Dublin, Ireland.

Spindler, Karen-Lise Garm ; Christensen, René dePont ; Fredslund Andersen, Rikke et al. / KRAS, BRAF, and PIK3CA mutations as predictors of outcome of maintenance therapy with bevacizumab with or without erlotinib after first line combination chemotherapy for mCRC. Results of the phase III Nordic ACT trial NCT00598156 translational study. Poster session presented at The 24th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Dublin, Ireland.

@conference{031d3abb0ff141d796f2a2598bd8bafc,

title = "KRAS, BRAF, and PIK3CA mutations as predictors of outcome of maintenance therapy with bevacizumab with or without erlotinib after first line combination chemotherapy for mCRC. Results of the phase III Nordic ACT trial NCT00598156 translational study",

author = "Spindler, {Karen-Lise Garm} and Christensen, {Ren{\'e} dePont} and {Fredslund Andersen}, Rikke and Niels Pallisgaard and Anders Johnsson and Anders Jakobsen",

year = "2012",

language = "English",

note = "The 24th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics ; Conference date: 06-11-2012 Through 09-11-2012",

}

Spindler, K-LG, Christensen, RD, Fredslund Andersen, R, Pallisgaard, N, Johnsson, A & Jakobsen, A 2012, 'KRAS, BRAF, and PIK3CA mutations as predictors of outcome of maintenance therapy with bevacizumab with or without erlotinib after first line combination chemotherapy for mCRC. Results of the phase III Nordic ACT trial NCT00598156 translational study', The 24th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Dublin, Ireland, 06/11/2012 - 09/11/2012.

KRAS, BRAF, and PIK3CA mutations as predictors of outcome of maintenance therapy with bevacizumab with or without erlotinib after first line combination chemotherapy for mCRC. Results of the phase III Nordic ACT trial NCT00598156 translational study. / Spindler, Karen-Lise Garm; Christensen, René dePont; Fredslund Andersen, Rikke et al.
2012. Poster session presented at The 24th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Dublin, Ireland.

Research output: Contribution to conference without publisher/journal › Poster › Research › peer-review

TY - CONF

T1 - KRAS, BRAF, and PIK3CA mutations as predictors of outcome of maintenance therapy with bevacizumab with or without erlotinib after first line combination chemotherapy for mCRC. Results of the phase III Nordic ACT trial NCT00598156 translational study

AU - Spindler, Karen-Lise Garm

AU - Christensen, René dePont

AU - Fredslund Andersen, Rikke

AU - Pallisgaard, Niels

AU - Johnsson, Anders

AU - Jakobsen, Anders

PY - 2012

Y1 - 2012

M3 - Poster

T2 - The 24th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Y2 - 6 November 2012 through 9 November 2012

ER -

Spindler KLG, Christensen RD, Fredslund Andersen R, Pallisgaard N, Johnsson A, Jakobsen A. KRAS, BRAF, and PIK3CA mutations as predictors of outcome of maintenance therapy with bevacizumab with or without erlotinib after first line combination chemotherapy for mCRC. Results of the phase III Nordic ACT trial NCT00598156 translational study. 2012. Poster session presented at The 24th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Dublin, Ireland.